These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31903178)

  • 1. Tocotrienol-rich vitamin E improves diabetic nephropathy and persists 6-9 months after washout: a phase IIa randomized controlled trial.
    Tan GCJ; Tan SMQ; Phang SCW; Ng YT; Ng EY; Ahmad B; Palamisamy UDM; Kadir KA
    Ther Adv Endocrinol Metab; 2019; 10():2042018819895462. PubMed ID: 31903178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial.
    Ng YT; Phang SCW; Tan GCJ; Ng EY; Botross Henien NP; M Palanisamy UD; Ahmad B; Abdul Kadir K
    Nutrients; 2020 May; 12(5):. PubMed ID: 32456230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease.
    Koay YY; Tan GCJ; Phang SCW; Ho JI; Chuar PF; Ho LS; Ahmad B; Abdul Kadir K
    Nutrients; 2021 Jan; 13(1):. PubMed ID: 33477404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial.
    Chuar PF; Ng YT; Phang SCW; Koay YY; Ho JI; Ho LS; Botross Henien NP; Ahmad B; Abdul Kadir K
    Nutrients; 2021 Oct; 13(11):. PubMed ID: 34836025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of vitamin E on non-proliferative diabetic retinopathy in type 2 diabetes mellitus: Are they sustainable with 12 months of therapy.
    Ho JI; Ng EY; Chiew Y; Koay YY; Chuar PF; Phang SCW; Ahmad B; Kadir KA
    SAGE Open Med; 2022; 10():20503121221095324. PubMed ID: 35652036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Khatami PG; Soleimani A; Sharifi N; Aghadavod E; Asemi Z
    J Clin Lipidol; 2016; 10(4):922-929. PubMed ID: 27578124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
    Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
    Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
    Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
    Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis.
    Musa AF; Dillon J; Md Taib ME; Yunus AM; Sanusi AR; Nordin MN; Smith JA
    J Cardiothorac Surg; 2021 Nov; 16(1):340. PubMed ID: 34819126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial.
    Liyanage P; Lekamwasam S; Weerarathna TP; Liyanage C
    J Postgrad Med; 2018; 64(1):10-15. PubMed ID: 29386413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
    Rejnmark L; Gosmanova EO; Khan AA; Makita N; Imanishi Y; Takeuchi Y; Sprague S; Shoback DM; Kohlmeier L; Rubin MR; Palermo A; Schwarz P; Gagnon C; Tsourdi E; Zhao C; Makara MA; Ominsky MS; Lai B; Ukena J; Sibley CT; Shu AD
    Adv Ther; 2024 Jun; 41(6):2500-2518. PubMed ID: 38691316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
    van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL
    Clin J Am Soc Nephrol; 2023 Jun; 18(6):748-758. PubMed ID: 36999981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
    Hanrahan JP; de Boer IH; Bakris GL; Wilson PJ; Wakefield JD; Seferovic JP; Chickering JG; Chien YT; Carlson K; Cressman MD; Currie MG; Milne GT; Profy AT
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):59-69. PubMed ID: 33328269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of endogenous antioxidant defense and the progression of kidney disease in multi-heritage groups of patients with type 2 diabetes: PRospective EValuation of Early Nephropathy and its Treatment (PREVENT).
    Earle KA; Zitouni K; Pepe J; Karaflou M; Godbold J
    J Transl Med; 2016 Aug; 14(1):234. PubMed ID: 27492324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.